Login to Your Account



Focus on the Core

Spinouts Popular Despite Difficulties Measuring ROI

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, November 7, 2011

As the biotech industry matured – and drug makers both big and small faced capital constraints – spinning off assets into separate companies developed into a popular mechanism to increase shareholder value.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription